PRA says Clinstar Takeover Offers Quicker and Cheaper Patient Enrollment

By Gareth Macdonald

- Last updated on GMT

Related tags: Eastern europe

PRA says Clinstar Takeover Offers Quicker and Cheaper Patient Enrollment
PRA says Clinstar Takeover Offers Quicker and Cheaper Patient Enrollment
US CRO PRA international has expanded its presence in Eastern Europe with the acquisition of privately-owned trial services firm ClinStar.

The deal – terms of which were not disclosed – adds ClinStar’s capabilities in Phase I – IV clinical trial management in Russia, Ukraine, Belarus and the Baltic states and its logistics division – IMP Logistics – to PRA’s network.

North Carolina, US-based PRA told it “will be able to leverage ClinStar’s substantial local presence and knowledge across all areas of operations within Russia and Eastern Europe to augment our current Eastern European operations.

PRA explained that it will work closely with clients to determine whether these regions are the right fit for a particular study design and suggested that - in those cases where the indication and standard of care align properly - clients could benefit from faster patient enrollment with fewer overall sites, saving time and money.

The contract research organisation (CRO) also said: “Over the coming months the 300 ClinStar and IMP Logistics employees will integrate with current PRA staff to form a cohesive team while maintaining successful operational delivery on projects. 

PRA will use this opportunity to augment not just its staff numbers but to also extend our expertise and experience with the ClinStar team that has focused exclusively on this region​.” 

No other takeovers planned

The acquisition follows just six months after privately-owned PRA secured a $410m (€326m) credit facility that Standard &Poor’s Rating Services suggested the CRO would use to fund geographic and capability expansion.

At the time the S&P analysts wrote: “We expect PRA to use the substantial flexibility under the new credit facility to grow the business through acquisitions and to pay dividends to its financial sponsor​.”

With this in mind we asked PRA whether any other deals are in the pipeline and it told us that: “No other acquisitions are planned at this time, but we are always willing to look at well run, high quality companies.”

The ClinStar deal follows just weeks after PRA announced that it had formed a joint venture (JV) in China with Wuxi Pharmatech​ which the US CRO told us was designed to build its presence in the country’s late stage trial sector.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more